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ABSTRACT
Osteosarcoma is the most common pediatric primary non-hematopoietic bone 
tumor. Survival of these young patients is related to the response to chemotherapy and 
development of metastases. Despite many advances in cancer research, chemotherapy 
regimens for osteosarcoma are still based on non-selective cytotoxic drugs. It is essential 
to investigate new specific molecular therapies for osteosarcoma to increase the survival 
rate of these patients. We performed exomic sequence analyses of 8 diagnostic biopsies 
of patients with conventional high grade osteosarcoma to advance our understanding 
of their genetic underpinnings and to correlate the genetic alteration with the clinical 
and pathological features of each patient to identify a personalized therapy.
We identified 18,275 somatic variations in 8,247 genes and we found three 
mutated genes in 7/8 (87%) samples (KIF1B, NEB and KMT2C). KMT2C showed the 
highest number of variations; it is an important component of a histone H3 lysine 4 
methyltransferase complex and it is one of the histone modifiers previously implicated 
in carcinogenesis, never studied in osteosarcoma. Moreover, we found a group of 15 
genes that showed variations only in patients that did not respond to therapy and 
developed metastasis and some of these genes are involved in carcinogenesis and 
tumor progression in other tumors.
These data could offer the opportunity to get a key molecular target to identify 
possible new strategies for early diagnosis and new therapeutic approaches for 
osteosarcoma and to provide a tailored treatment for each patient based on their 
genetic profile.
INTRODUCTION
Osteosarcoma is the most common non-
haematological primary malignant tumor of the bone, it 
arises from mesenchymal cells that produce osteoid and 
immature bone and affects mainly the extremities of 
adolescents and young adults [1–2]. 
The 5-years survival rate for patients with 
osteosarcoma without evidence of metastasis is 60% to 
65%, whereas it is only 20% to 28% for osteosarcoma 
patients with metastases at the time of diagnosis [3]. 
Treatment of high grade osteosarcoma is based on a 
multidisciplinary approach that includes neoadjuvant 
chemotherapy, surgical excision of the primary tumor and 
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metastasis excision; evaluation of response to therapy in 
the surgical specimen is crucial to eventually schedule 
a postoperative chemotherapy [4]. Standard therapy 
regimens often involve the use of high-dose methotrexate, 
doxorubicin, cisplatin and ifosfamide [4–5]. Evaluation 
of response to therapy was assessed by percentage area 
of necrosis in the specimen after surgery; patients who 
respond to therapy showing tumor necrosis ≥ 90% after 
surgery and they do not develop metastasis (Responder) 
while patients that do not respond to neoadjuvant 
chemotherapy showing tumor necrosis ≤ 90% after surgery 
and eventually developing metastasis (Non-responder) [6].
Although the survival rate has improved 
considerably after the introduction of neoadjuvant 
chemotherapy and surgery, metastatic or recurrent disease 
still occurs and the survival rate of patients is mainly 
linked to the resistance to therapy and to the development 
of metastasis [7]. In patients with metastatic osteosarcoma 
treated with neoadjuvant therapy, the “Responder” status 
shows improved survival (82% at 5-years) compared 
to “Non-Responder” (70% at 5-years) [8–9]. Over the 
last decade, scientific research has provided essential 
information about the pathogenic, molecular and 
biochemical pathway involved in osteosarcoma [10–11]; 
however, molecular mechanisms related to carcinogenesis, 
progression and resistance to therapy are still largely 
unknown. Indeed, even now the osteosarcoma karyotype 
is considered complex and only mutations of tumor 
suppressors genes TP53 and RB1 are commonly associated 
with the development of osteosarcoma [12].
There are many examples of “molecular targeted 
therapy”, where tailored therapeutic agents have been 
selected to aim against specific molecules and their 
downstream effector pathways in each patient [13]. 
Nonetheless survival rates of patients have not greatly 
improved [14], as little is known at genetic level about the 
pathogenesis of osteosarcomas resulting in a lack of more 
effective and tailored chemotherapy drug regimens [15].
Our hypothesis is that only the analysis of the entire 
coding genome could lead to a better understanding of the 
molecular mechanisms underlying the development and 
progression of osteosarcoma. Next generation sequencing 
(NGS) technologies can unveil DNA sequences whose 
study can be applied to characterize both common and 
rare genomic alterations across cancer types. The NGS 
approach could clarify the landscape of genetic alteration 
in osteosarcoma and provide relevant biological data. In 
particular, the knowledge of genetic alterations in coding 
exon regions, through WES (Whole Exome Sequencing) 
approach, may result in an easier discovery of new 
proteins as molecular target which could be aimed at 
personalized therapies. Indeed, WES could lead to create 
algorithms to identify relevant genetic alterations networks 
relevant to the clinical context of the disease [16–18]. The 
aim of this study was to perform WES analysis in selected 
tumors samples of osteosarcoma, both from responder and 
non-responder patients that developed metastasis. The 
goal will be to improve the knowledge of osteosarcoma 
carcinogenesis, progression and resistance to therapy, to 
identify new strategies for therapeutic approaches and 
personalized therapy. 
RESULTS
Sequence coverage and mutation analysis
This analysis provided a vast new reservoir of data 
and, after filtering the data, within our discovery set of 
eight osteosarcomas, 5 responder and 3 non-responder, we 
identified 18,275 somatic variations in 8,247 genes. The 
number of coding variations in each sample ranged from 
496 to 8,500 with an average of 2,347.5 variations. All 
the variations were missense and the 98.5% were SNVs 
(Single Nucleotide Variants) while the 1.5% were MNPs 
(Multiple Nucleotide Polymorphisms).
The mutation rate in the responder group was 
slightly higher than the non-responder group (Table 1, 
Figure 1). Moreover, we found that, as in several other 
cancers [19], C:G>T:A transitions were the most 
predominant somatic substitution both in the responder 
group (43%) and in the non-responder group (34%) and 
we found that the vast majority of these transitions were 
identified in the context of 5’-CpG-3’ dinucleotide as 
the result of a 5’-methylcytosine deamination (data not 
shown).
We did not find common mutated genes in all 
eight samples but we found three mutated genes (KIF1B, 
NEB, KMT2C) in 7/8 (87%) samples. Seventeen genes 
were mutated in 6 samples (75%, 6/8) and 57 genes 
showed variations in 5 samples (62.5%, 5/8). We noted 
a great variability of genes mutated among the samples 
as shown in Supplementary Table 1. Indeed, taking 
into consideration common mutated genes in at least 5 
samples, we noted that sample n°5 showed variations in 
77 genes while the sample n°6 showed variations only in 
22 genes (Supplementary Table 1).
These 77 genes that were found mutated in more 
than half of the samples are involved in important 
biological processes such as transcription regulation, ion 
transport, DNA damage and repair, cell adhesion and 
angiogenesis (Table 2). 
Despite variations of TP53 and RB1 are associated 
with development of human osteosarcoma, we found 
that variations of TP53 were present in only one patient 
(12.5%, sample n°5) while only two patients showed 
variations of RB1 gene (25%, sample n°1 and 5).
Genes that may be involved in osteosarcoma 
tumorigenesis
We found that KIF1B, NEB and KMT2C were 
the only three genes mutated in 7/8 samples. KIF1B is 
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located on chromosome 1p36, and belongs to the kinesin 
superfamily of intermediate filaments [20]. NEB, maps 
to chromosome 2q22, encodes nebulin, a giant protein 
component of the cytoskeletal matrix [21]. We found 10 
and 27 variations respectively in these two genes and they 
were mutated in all samples except in sample n°7, while 
Table 1: N° of variations and variation rate (n° of variations/Mb) of responder and non-responder 
osteosarcoma patients
Sample N° of variations Variations rate Status
1 1390 118.8 Responder
5 8500 726.5 Responder
6 496 42.4 Responder
7 791 67.6 Responder
8 802 68.5 Responder
2 4211 359.9 Non-Responder
3 1495 127.8 Non-Responder
4 1095 93.6 Non-Responder
Table 2: Genes mutated in more than half of the osteosarcoma patients and their biological functions
Biological function Mutated genes
Transcription regulation 
ATF2; BPTF; CHD7; DENND4A; HIVEP2; IKBKAP; JMJD1C; KMT2C; KMT2E; 
MYCBP2; NCOR1; RFX7; SPEN; 
Transport
ABCB5; ABCD2; ANKH; ATP10D; CACNA2D3; DGKD; HERC1; ITPR1; SLC8A1; 
SLC9B1; TRPM3;
Cell Adhesion DST; FN1; ITGA6; MPDZ; NRXN2; RELN;
Immunity C5; CFH; PKHD1L1; 
Apoptosis BIRC6; ITPR1; KIF1B;
Endocytosis DGKD; LRP2; STAB2;
Cell cycle ALMS1; ATM; BIRC6; KMT2E;
DNA damage ATF2; ATM; DNA2; POLQ; PRDM10; PSME4;
Angiogenesis FN1; THSD7A;
Ubl conjugation pathway BIRC6; HECTD1; HERC1; MYCBP2;
Wnt signaling pathway MACF1;
Differentiation ABCB5; OBSCN; PSME4; THSD7A;
DNA repair DNA2; POLQ; PRDM10; PSME4;
Muscle development DMD; NEB; SYNE1; UTRN;
Regulation of bone mineralization ENPP1; FBN2; 
Cell communication FRAS1;
mRNA processing FRG1;
Nucleotide metabolism NT5C2;
Multicellular organism 
development PRTG;
Regulation of cell migration SYNE2;
Small GTPase mediated signal 
trasduction DOCK5;
Regulation of GTPase activity AKAP13; DENND4A; PREX2; SYDE2;
Extracellular matrix organization EGFLAM;
Microtuble-based movement DNAH9; DNAH10;
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sample n°5 had the higher number of variations in both 
cases (Table 3). Finally, KMT2C is located on chromosome 
7q36.1 and it is a member of the mixed-lineage leukemia 
(MLL) family and it has histone H3 lysine-specific 
methylation activity. KMT2C is an important component 
of histone H3 lysine 4 methyltransferase complex, 
implicated in chromatin remodelling, called ASCOM 
(ASC-2-and Mll3-containing complex) [22].
Among these three genes, KMT2C showed the 
highest number of variations: we found 36 variations, with 
sample n°5 revealing the highest number of variations, 
except in sample n°3 (Table 4). Particularly, sample 
n°3 was a 14-year old boy with diagnosis of high grade 
chondroblastic osteosarcoma made on femur biopsy 
(stage IVa), follow-up was 11 years, he did not respond to 
neoadjuvant chemotherapy and develop metastasis. 
Genes that may be involved in osteosarcoma 
metastatic progression and resistance to therapy
We found that 0.18% (15/8247) of genes showed 
variations, all missense (94% SNV, 6% MNP), only in 
the non-responder group (Table 5). Categorizing them by 
KEGG pathway analysis and literature review, we found 
that some of these are involved in important biological 
processes (Table 6). ERBB4 is located on chromosome 
2q34 and it is a receptor tyrosine kinase member of the 
epidermal growth factor receptor (EGFR) family [23]. 
ERBB4 is involved in biological process such as signal 
transduction, transport and catabolism. It is involved in 
human disease like cancer: it participates in pathways such 
as ERBB signalling, implicated in tumor migration and 
invasion, and in other pathway implicated in inhibition of 
tumor angiogenesis [24]. In signal transduction, transport 
and catabolism and human disease biological process is 
involved THBS1 too and moreover is implicated in cell 
growth and death process. THBS1, thrombospondin 1, 
is located on chromosome 15q14 [25] and it is involved 
in RAP1 and TP53 signalling pathways, involved in 
inhibition of angiogenesis and metastasis, in PI3K-AKT 
and TGF-beta signalling pathway, involved in the control 
of cell cycle and apoptosis, and it takes part in focal 
adhesion and ECM-receptor interaction process [26]. 
Other genes are enzymes with specific activity like as 
rRNA and tRNA biogenesis (DIS3, KARS), spliceosome 
activity (BCLAF1) or charboidrate metabolism (PDHX) 
and all involved in carcinogenesis [27–32].
DISCUSSION
Osteosarcoma is a heterogeneous tumor and it 
is a so-called “orphan cancer” with no known driver 
oncogenes [33]. It is essential to find useful biomarkers 
and to detect the potential targets for new drugs, to 
increase overall survival of these patients. This could 
be done only if we better understand the complex 
biology of this tumor and the molecular pathways that 
lead to the development of metastases and resistance to 
therapy. At present time, the most innovative approach 
is represented by NGS, which allows to analyse the 
entire human genome [18]. In this study, we performed 
the analysis of exomic sequences of osteosarcomas to 
advance our understanding of their genetic underpinnings 
and to correlate the genetic alterations with the clinical 
and pathological features of each patient. Our aim was 
to identify clinically relevant variations in the landscape 
of somatic events in osteosarcoma pathogenesis and 
so we performed WES analysis on eight high grade 
osteosarcoma biopsies. Using stringent criteria for the 
analysis of these presumptive variations, we identified 
18,275 somatic variations, all missense, in 8,247 genes. 
We noted that the mutation rate was similar between 
responder and non-responder group but overall this rate 
was higher than previous studies probably due to the 
small number of our samples [34–36]. We did not find 
specific structural abnormalities common to all samples, 
such as specific translocations like other sarcomas (e.g. 
Ewing sarcoma EWS/FLI1 t(11;22)(q24;q12)), confirming 
the complexity of osteosarcoma karyotype [15]. Despite 
TP53 and RB1 genes are considered top driver genes in 
osteosarcoma cancerogenesis, our study showed lower 
mutation frequency of TP53 and RB1 than other studies 
[34,35,37–39]. Indeed, we observed that only one patients 
(12.5%, 1/8) showed variations of TP53 gene and that 
only two patients showed variations of RB1 gene (25%, 
2/8). Our results could be the effect of the small number 
of samples, however the range of mutation rate described 
in osteosarcoma is very large going from 31% to 82% 
and from 19% to 64% for TP53 and RB1 respectively 
[41]. Moreover, most TP53 mutations described in some 
studies, are structural variations in intron 1 [34, 37, 38] 
that we did not study and the mutation rate outside the 
intron 1 is low (19–20%) [34, 40]. However, as reported 
in literature, among all mutations of TP53 reported in 
previous studies only some mutations are clonal events 
[37]. Lastly, our data was filtered by Sift and Polyphen-2 
bioinformatics software, so we reported only mutations 
that are considered deleterious for the protein function.
However, beyond TP53 and RB1, between genes 
considered candidate driver genes in osteosarcoma 
carcinogenesis [36] we found that ATM, a gene involved 
in DNA damage control signalling pathway, showed 
variations in 5/8 osteosarcoma samples. ATM is a tumor 
suppressor gene that belongs to the family of proteins 
that respond to DNA damage by phosphorylating key 
substrates involved in DNA repair and/or cell cycle 
control [36]. Moreover, we did not find variations in genes 
associated at inherited cancer predisposition syndromes 
associated with osteosarcoma as RECQL4, BLM, and 
WRN [34, 35, 37].
Moreover, we did not find variations common to all 
osteosarcoma samples but we found three mutated genes in 
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7/8 samples (87%) never studied in osteosarcoma. Variations 
in these three genes may be early molecular events and so 
they may be related to osteosarcoma tumorigenesis. KIF1B 
is responsible for intracellular vesicular transport [20], a 
process involved in the production matrix in osteosarcoma 
[42]. KIF1B has been shown to act as a tumor suppressor 
in multiple cancers by acting on various inhibitors of cell 
proliferation and activators of apoptosis [20]. Another 
interesting NEB, maps to chromosome 2q22, encodes 
nebulin, a giant protein component of the cytoskeletal 
matrix [21], that coexists with thick and thin filaments 
within the sarcomeres of skeletal muscle [21].
Table 3: Somatic variation of KIF1B and NEB in Osteosarcoma samples and their genomic and 
aminoacid change
Sample Gene Genomic change Aminoacid
1 KIF1B c.650C>T p.Ser217Phe
1 KIF1B c.5074G>A p.Asp1692Asn
1 NEB c.21268C>T p.Pro7090Ser
1 NEB c.21197T>A p.Leu7066His
2 KIF1B c.177T>A p.His59Gln
2 NEB c.23803A>G p.Arg7935Gly
2 NEB c.20167C>G p.Arg6723Gly
2 NEB c.20167C>T p.Arg6723Trp
2 NEB c.20165A>G p.Tyr6722Cys
2 NEB c.20165A>T p.Tyr6722Phe
2 NEB c.19249_19250delTAinsCA p.Tyr6417His
2 NEB c.19063T>A p.Tyr6355Asn
3 KIF1B c.2798A>G p.Tyr933Cys
3 NEB c.7325T>A p.Ile2442Asn
4 KIF1B c.5069A>G p.Asp1690Gly
4 NEB c.11109G>C p.Lys3703Asn
5 KIF1B c.538G>A p.Asp180Asn
5 KIF1B c.2332G>A p.Val778Met
5 KIF1B c.2344G>A p.Glu782Lys
5 NEB c.23570A>G p.Glu7857Gly
5 NEB c.22337T>C p.Ile7446Thr
5 NEB c.22333G>C p.Asp7445His
5 NEB c.22021G>C p.Ala7341Pro
5 NEB c.21991G>T p.Ala7331Ser
5 NEB c.21569C>T p.Thr7190Ile
5 NEB c.18996G>C p.Gln6332His
5 NEB c.18448G>C p.Asp6150His
5 NEB c.11026G>A p.Asp3676Asn
5 NEB c.8156A>T p.Asn2719Ile
5 NEB c.8142T>G p.Asn2714Lys
5 NEB c.2633G>C p.Ser878Thr
6 KIF1B c.956C>T p.Thr319Ile
6 NEB c.9705C>A p.Asn3235Lys
6 NEB c.7025G>A p.Ser2342Asn
8 KIF1B c.3814C>T p.Arg1272Cys
8 NEB c.10286C>T p.Thr3429Ile
8 NEB c.9692T>G p.Leu3231Trp L
Oncotarget6www.impactjournals.com/oncotarget
Finally, KMT2C catalyses the monomethylation 
of H3K4 in collaboration with hormone receptors and 
transcription factors involved in developmental signalling 
[22, 43]; it is one of the histone modifiers previously 
implicated in some cancer types [22]. It caught our attention 
showing more variations than KIF1B and NEB, finally 
because this gene is found to be inactivated in other tumors 
causing an alteration of tumor suppressor gene TP53 [43], 
which is also frequently altered in osteosarcoma [44]. 
Moreover, recent evidence showed that mutations of KMT2C 
can modify its cooperation with oestrogen receptor [45], this 
hormone playing a key role in the development and support 
of bone remodelling and matrix production [46]. Recently, 
it has been demonstrated that highly conserved epigenetic 
Table 4: Somatic variations of KMT2C in Osteosarcoma samples and their genomic and aminoacid 
change
Sample Genomic change Aminoacid
1 c.2963G>T p.Cys988Phe
1 c.8326G>A p.Glu2776Lys
1 c.11927C>A p.Pro3976Gln
1 c.12014C>T p.Ser4005Phe
1 c.14521G>A p.Gly4841Arg
2 c.1277C>A p.Pro426Gln
2 c.6632G>C p.Arg2211Thr
2 c.5459C>G p.Ser1820Cys
2 c.8174A>G p.Glu2725Gly
2 c.9622T>C p.Ser3208Pro
2 c.9617G>C p.Arg3206Thr
4 c.10383T>G p.Asp3461Glu
5 c.404C>T p.Ala135Val
5 c.3155A>T p.Lys1052Ile
5 c.3119C>A p.Pro1040Gln
5 c.3029G>T p.Cys1010Phe
5 c.5669G>C p.Arg1890Pro
5 c.7318C>T p.Pro2440Ser
5 c.7214A>G p.Glu2405Gly
5 c.9182A>G p.Gln3061Arg
5 c.9769G>A p.Glu3257Lys
6 c.925C>T p.Pro309Ser
6 c.1181G>A p.Cys394Tyr
6 c.2512G>A p.Gly838Ser
6 c.2468T>C p.Ile823Thr
6 c.2459C>T p.Thr820Ile
6 c.2656C>T p.Arg886Cys
7 c.943G>A p.Gly315Ser
7 c.925C>T p.Pro309Ser
7 c.2512G>A p.Gly838Ser
7 c.2468T>C p.Ile823Thr
7 c.2963G>T p.Cys988Phe
7 c.2917A>G p.Arg973Gly
8 c.943G>A p.Gly315Ser
8 c.2512G>A p.Gly838Ser
8 c.2468T>C p.Ile823Thr
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Table 5: Variations of genes mutated only in non-responder group and their genomic and 
aminoacid change
Gene Genomic change Aminoacid
ALDH1L2 c.484G>A p.Gly162Ser
ALDH1L2 c.1732A>C p.Thr578Pro
ALDH1L2 c.2086G>A p.Gly696Ser
BCLAF1 c.491A>C p.Lys164Thr
BCLAF1 c.1646T>C p.Leu549Pro
BCLAF1 c.1742A>T p.Lys581Met
CLCN1 c.823_825delGTCinsGGG p.Val275Gly
CLCN1 c.1289A>C p.Asn430Thr
CLCN1 c.1574C>G p.Ala525Gly
CLCN1 c.1073G>A p.Cys358Tyr
CLCN1 c.1427C>G p.Thr476Ser
COG3 c.943G>C p.Glu315Gln
COG3 c.505A>G p.Thr169Ala
COG3 c.1411T>A p.Tyr471Asn
DIS3 c.2312_2313delTAinsAA p.Ile771Lys
DIS3 c.2252C>G p.Ala751Gly
DIS3 c.2234C>T p.Thr745Ile
DIS3 c.2458C>T p.Arg820Trp
ERBB4 c.2761T>A p.Tyr921Asn
ERBB4 c.1541G>A p.Gly514Glu
ERBB4 c.1841G>A p.Cys614Tyr
KARS c.398T>C p.Leu133Pro
KARS c.1009G>T p.Val337Phe
KARS c.1066G>A p.Asp356Asn
OR52N1 c.589A>G p.Asn197Asp
OR52N1 c.569C>G p.Ser190Cys
OR52N1 c.53G>C p.Gly18Ala
OR52N1 c.82T>C p.Trp28Arg
PDE6C c.646T>A p.Tyr216Asn
PDE6C c.650T>C p.Leu217Pro
PDE6C c.1289G>A p.Gly430Glu
PDE6C c.1992G>T p.Leu664Phe
PDHX c.566G>C p.Arg189Pro
PDHX c.626G>A p.Gly209Glu
PDHX c.323G>A p.Gly108Glu
SCN8A c.2276T>C p.Ile759Thr
SCN8A c.4048G>A p.Ala1350Thr
SCN8A c.677G>A p.Arg226Lys
SP140L c.1425A>C p.Lys475Asn
SP140L c.329T>A p.Leu110His
SP140L c.1013C>A p.Pro338His
THBS1 c.634C>G p.Leu212Val
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regulators are frequently mutated in cancer [47]; indeed, some 
studies suggest that variations in the coding sequences of 
regulatory elements, that act on enhancers to recognize specific 
transcription factors, could be the cause of tumor development 
[47]. KMT2C acts in collaboration with hormone receptors 
and transcription factors involved in growth-promoting 
pathways and it performs its action at transcription enhancer 
regions [22]. KMT2C is frequently mutated in a broad 
spectrum of cancers and it has been related to tumorigenesis 
[48]. Therefore, our hypothesis is that KMT2C could be 
involved in osteosarcoma carcinogenesis too.
We found that the responder group showed more 
variations than the non-responder group and we noted 
that 15 genes showed variations only in the non-responder 
group which subsequently developed a metastatic disease. 
We found that some of them are involved in carcinogenesis 
and tumor progression but not in osteosarcoma. 
Particularly, ERBB4 is a member of the Tyr protein kinase 
family and the epidermal growth factor receptor subfamily 
that regulates cell proliferation and differentiation [23]. 
It has been shown that ERBB4 is overexpressed in 
Ewing Sarcoma cell lines derived from chemoresistant 
or metastatic Ewing sarcoma, a tumor of the bone [24]. 
ERBB4 leads to activation of PI3K-AKT, focal adhesion 
kinase (FAK) and the RAC1 GTPase, a mediator of cell 
migration and invasion [24], pathways that are already 
been described in osteosarcoma pathogenesis [49–50].
ERBB4 is rarely mutated in human cancers [51] 
but recently it was shown that ERBB4 can inhibit the 
tumor suppressor TP53 by regulating the MDMX-MDM2 
complex stability, the primary inhibitors of TP53, leading 
to TP53 inactivation in tumor [52]. Thrombospondin 
I (THBS1) is an endogenous inhibitor of angiogenesis, 
which limits blood vessel density in normal tissues and 
curtails tumor growth. It interacts with a variety of ECM 
molecules and cell surface receptors and this protein has 
been shown to play roles in tumorigenesis; particularly, 
it was showed that THBS1 induced cell migration 
in several tumor cell lines suggesting that THBS1 is 
involved in cancer invasion [26]. DIS3 is one of catalytic 
components of the human RNA processing and degrading 
exosome it has both endonucleolytic and 3-prime/5-prime 
exonucleolytic activity [27]; mutations in DIS3 have been 
observed in several cancer types [28] and in multiple 
myeloma was observed a shorter survival in patients with 
DIS3 mutations [29]. BCLAF1 encodes a transcriptional 
THBS1 c.1699_1700delGAinsGT p.Asp567Val
THBS1 c.2365G>A p.Asp789Asn
THBS1 c.1532G>C p.Gly511Ala
UBE4A c.1130T>A p.Ile377Asn
UBE4A c.2209G>A p.Glu737Lys
UBE4A c.3136G>T p.Asp1046Tyr
ZNF12 c.137C>G p.Ser46Cys
ZNF12 c.1265C>T p.Ser422Phe
ZNF12 c.2086C>T p.Leu696Phe
Figure 1: Histogram of the mutation rate in responder and non-responder group.
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repressor that interacts with several members of the BCL2 
family of proteins and ectopical BCLAF1 expression 
induces apoptosis in various cell types or autophagic 
cell death in myeloma cells. It was hypothesized that 
BCLAF1 plays a critical role repressing the transcription 
of survival genes through TP53 inhibition. Moreover, it 
was found that tumor cells suppress BCLAF1 expression 
inducing a cascade of antiapoptotic cellular events 
that all together determine an increase survival of 
tumor cells [31]. The KARS gene encodes lysyl-tRNA 
synthetase, which catalyses the aminoacylation of tRNA-
lys in the cytoplasm and mitochondria. It was showed 
that it was implicated in cancer metastasis indeed the 
phosphorylation of KARS at the Thr52 residue by 
p38MAPK, causes the dissociation from the cytosolic 
multi-tRNA synthetase complex and the following 
translocation to the plasma membrane, where it associates 
with a 67 kDa laminin receptor (p67LR) involved in 
migration and metastasis [30]. The PDHX gene encodes 
component X of the pyruvate dehydrogenase (PDH) 
complex that is in the mitochondrial matrix and catalyzes 
the conversion of pyruvate to acetyl coenzyme A [32]. 
It was showed that in colorectal cancer cells the glucose 
metabolism was regulated by miR-26a direct targeting 
the PDHX, which inhibits the conversion of pyruvate to 
acetyl coenzyme A in the citric acid cycle to require the 
glucose uptake to the energy needs of cancer cells [32]. In 
successive studies, it will be necessary to study whether 
and how these mutations may modify the expression of 
these genes and the function of the associated protein to 
discovery a possible molecular target.
Some of these genes identified in our study are 
involved in metastatic progression and poor survival 
in tumors, also of mesenchymal origin, but these have 
never been studied in osteosarcoma [24, 26, 29, 30]. 
Our hypothesis is that alterations in these genes could be 
involved in a mechanism of metastatic progression and 
drug resistance in osteosarcoma.
We recognize these preliminary results may arise 
due to the small sample size, which is a limitation of the 
study, and we believe that it will be necessary first to 
ascertain our data in a larger cohort of patients.
In conclusion, our WES analysis confirms that the 
osteosarcoma karyotype is complex, however, we found 
genes probably involved in osteosarcoma carcinogenesis, 
as KMT2C, and we identified a group of 15 genes probably 
involved in metastasis development and drug resistance 
that could offer the opportunity to identify potential 
drug targets in order to create a personalized therapy 
and increase the survival rate among young patients with 
osteosarcoma.
MATERIALS AND METHODS
Population study
The population of this study included 8 diagnostic 
biopsies of patients with conventional high grade 
osteosarcoma (sec. Enneking classification) obtained 
before neoadjuvant therapy from the files of the 
Department of Medical and Surgical Sciences and 
Biotechnologies, Sapienza University of Rome, Polo 
Table 6: Mutated genes in non-responder group of osteosarcoma patients and their chromosomal 
location and biological process
Gene Chromosomal location Biological process
ALDH1L2 12q23.3 Metabolism of cofactors and vitamins
BCLAF1 6q23.3 Spliceosome
CLCN1 7q34 Ion channels 
COG3 13q14.13 Membrane trafficking
DIS3 13q22.1 mRNA biogenesis
ERBB4 2q34 Signal trasduction, Transport and catabolism, Human disease
KARS 16q23.1 tRNA biogenesis
OR52N1 11p15.4 Olfactory transduction
PDE6C 10q24 Sensory transduction
PDHX 11p13  Carbohydrate metabolism
SCN8A 12q13 Ion channels 
SP140L 2q37.1 unknown
THBS1 15q15 Signal trasduction, Transport and catabolism, Human 
disease, Cell growth and death
UBE4A 11q23.3 Ubiquitin mediated proteolysis
ZNF12 7p22.1 Transcription factors
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Pontino, ICOT, Latina, Italy. The WHO 2008 classification 
of bone tumors was used for classifying and staging 
the bone lesions. Patients had a mean follow-up time 
of 9 years (range 1–14 years), 50% of them showed a 
minimum 5-years overall survival. Evaluation of response 
to therapy was assessed by percentage area of necrosis 
in the specimen after surgery; out of these 8 patients, 5 
(identified as “responder”) responded to therapy showing 
tumor necrosis ≥ 90% after surgery and didn’t develop 
metastasis while 3 patients did not respond to neoadjuvant 
chemotherapy showing tumor necrosis ≤ 90% after surgery 
and developed metastasis (identified as “non-responder”). 
There were not inherited cancer predisposition syndromes 
associated with osteosarcoma among our samples. 
The clinical and pathological characteristics of each 
osteosarcoma patients are described in Table 7. All the 
tissue samples were reviewed on microscopy examinations 
by two dedicated pathologists.
Whole-exome sequencing (WES)
Genomic DNA was extracted from FFPE 
osteosarcoma biopsies using RecoverAll Total Nucleic 
Acid isolation FFPE kit (Life Technologies, Foster City, 
CA) according to the manufacturer’s instruction and was 
used to prepare fragment libraries suitable for massively 
parallel paired-end sequencing. 
DNA was amplified with GenomePlex Single 
Cell Whole Genome Amplification kit, following the 
manufacturer’s protocol, because of the degraded material, 
typical of osteosarcoma samples. We measured DNA 
concentration of the samples using Qubit 2.0 Fluorometer 
(Invitrogen, Life Technologies, Grand Island, NY) with 
the Qubit DNA HS assay kit or Qubit DNA BR Assay 
kit according to the quantity of the starting material. 
Moreover, we checked the quality of DNA with 2200 
Tapestation Instrument (Agilent Technologies, Santa 
Clara, CA, USA) using the D1000 screen tape or the High 
sensitivity D1000 screen tape as appropriate, to see the 
level of fragmentation of our samples.
To prepare the DNA library we used Nextera Rapid 
Capture Expanded Exome Kit (Illumina, San Diego, CA, 
USA) following the guidelines of the protocol but we 
used the half of the amount of the fragmentation enzyme 
because of the high level of fragmentation of all the 
samples tested with Tapestation. We load a maximum of 5 
pooling libraries for each cartridge NextSeq High Output 
(300 cycles) on NextSeq500 (Illumina, San Diego, CA, 
USA).
WES data analysis
We sequenced the whole exomes of eight high-
grade osteosarcoma tissues using NextSeq550 Illumina 
platform. The instrument generated approximately an 
average read length of 120.6 bases. After mapping to the 
human reference genome GRCh37 (hg19) using Burrows-
Wheeler Alignment tool (BWA), we obtained the average 
depth of each base in the target regions as 17.7x. The 
average coverage of target regions was 121.7x.
The raw data generated from Illumina NextSeq550 
were converted using Bcl2toFastq tools provided by 
Illumina. The data analysis of exomes was performed 
by using the SeqMule pipeline1. The final Variant Call 
Table 7: Clinicopathological characteristics of 8 osteosacoma patients
Sample Sex Age Histological type* Grading** Staging* Site
Follow-up 
(Years) Status
1 F 29
Conventional 
Osteosarcoma High grade IIB Jaw 14 Responder
2 M 30
Conventional 
Osteosarcoma High grade III Femur 3 Non-Responder
3 M 14
Chondroblastic 
osteosarcoma High grade IVA Femur 11 Non-Responder
4 M 35
Conventional 
Osteosarcoma High grade III Femur 1 Non-Responder
5 M 21
Conventional 
Osteosarcoma High grade III Femur 13 Responder
6 M 11
Conventional 
Osteosarcoma High grade III Femur 5 Responder
7 F 24
Conventional 
Osteosarcoma High grade IIB Mandible 12 Responder
8 M 31
Chondroblastic 
osteosarcoma High grade IIA Jaw 13 Responder
*Sec. WHO 2008
** Sec. Enneking grade
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Format files (VCFs) were uploaded on the VariantStudio 
Illumina (Illumina San Diego, CA, USA) software 
to perform annotation and filtration steps. We filtered 
genomic data by quality score of 30, by mean read depth 
of 5, and by GMAF ≤ 1 (Global Minor Allele Frequency: 
the frequency of the second most frequent allele in the 
population). Next, the detected mutations were filtered 
for the variants absent in database of Single Nucleotide 
Polymorphisms (dbSNP) to distinguish known somatic 
mutations from germline mutations. We further selected 
the somatic variations in the coding sequence by excluding 
those variations in flanking sequences like splicing sites, 
5ʹ-UTR, 3ʹUTR, introns and intergenic regions. Moreover, 
we performed bioinformatics analysis using SIFT (v4.0.3) 
and PolyPhen-2 (v2.1.0) tools, that predict whether an 
amino acid substitution affects protein function based 
on sequence homology. To be sure that the variations to 
study were only those that caused a protein alteration, we 
selected only those that were at the same time deleterious 
for SIFT and probably damaging for PolyPhen-2.
Validation of variations
Genes that showed variation in the 87% of 
osteosarcoma samples (KIF1B, NEB and KMT2C) were 
selected for target resequencing and validation by Sanger 
sequencing. DNAs were amplified using the Gene Amp 
PCR System 9700 (Life Technologies, Foster City, CA). 
The PCR products were then purified using Exosap-IT 
(Affymetrix, Santa Clara, CA) and then sequenced using 
Big Dye Terminator version 1.1 Cycle Sequencing Kit 
(Life Technologies, Foster City, CA). Unincorporated 
primers and dye terminators were removed using the 
Montage-SEQ96 Sequencing Reaction Cleanup Kit 
(Merck Millipore, Billerica, MA). Sequencing was 
performed on an ABI PRISM 3100 Genetic Analyzer 
(Life Technologies, Foster City, CA) with 3100 Genetic 
Analyzer Data Collection software version 1.1. The 
sequencing and each reaction were performed in triplicate.
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